For type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic risk

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)39-40
Number of pages2
JournalEvidence-based Medicine
Volume16
Issue number2
DOIs
Publication statusPublished - Apr 2011

Cite this